Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Menu

Actinium Pharmaceuticals Inc (ATNM)

Actinium Pharmaceuticals Inc (ATNM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Amarin's Q3 Earnings In Line, Revenues Fall Shy of Estimates
Amarin's Q3 Earnings In Line, Revenues Fall Shy of Estimates Zacks Investment Research - Thu Oct 31, 12:12PM CDT

Amarin Corporation plc AMRN reported an adjusted loss of 5 cents per share for the third quarter of 2024, which was in line with the Zacks Consensus Estimate. The company had reported breakeven earnings...

FOLD : 9.80 (+0.72%)
AMRN : 0.4600 (-1.18%)
ARDX : 4.82 (+2.77%)
ATNM : 1.2900 (+15.18%)
Corcept Trumps Q3 Earnings & Sales Estimates, Ups '24 Revenue View
Corcept Trumps Q3 Earnings & Sales Estimates, Ups '24 Revenue View Zacks Investment Research - Thu Oct 31, 12:12PM CDT

Corcept Therapeutics Incorporated CORT reported third-quarter 2024 earnings of 41 cents per share, which significantly beat the Zacks Consensus Estimate of 27 cents. The company had reported earnings of...

FOLD : 9.80 (+0.72%)
CORT : 51.40 (+0.49%)
ARDX : 4.82 (+2.77%)
ATNM : 1.2900 (+15.18%)
Treatment of Blood Cancers - Biopharma Companies Building out their Pipeline of Solutions Newsfile - Tue Jun 18, 7:50AM CDT

Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - June 18, 2024) - Investorideas.com, a go-to investing platform covering biotech and medical technology stocks releases the second of a...

ATNM : 1.2900 (+15.18%)
Acute Myeloid Leukemia Market Size Expected to Reach $2.97 Billion By 2029 as Clinical Trials Increase FinancialNewsMedia - Mon Jun 17, 8:45AM CDT

EQNX::TICKER_START (NYSE:ATNM),(NASDAQ:BPTH),(NASDAQ:LGVN),(NASDAQ:SLS),(NYSE:BMY) EQNX::TICKER_END

ATNM : 1.2900 (+15.18%)
BPTH : 1.2600 (-15.44%)
LGVN : 1.6500 (+3.12%)
SLS : 0.8880 (-1.11%)
BMY : 57.33 (+1.83%)
Acute Myeloid Leukemia Market Size Expected to Reach $2.97 Billion By 2029 as Clinical Trials Increase GlobeNewswire - Mon Jun 17, 8:45AM CDT

ATNM : 1.2900 (+15.18%)
BPTH : 1.2600 (-15.44%)
LGVN : 1.6500 (+3.12%)
SLS : 0.8880 (-1.11%)
BMY : 57.33 (+1.83%)
Acute Myeloid Leukemia is on the Rise as Biotechs Race to Develop Groundbreaking Therapies FinancialNewsMedia - Mon Jun 17, 8:00AM CDT

EQNX::TICKER_START (NYSE:ATNM),(NASDAQ:SNDX),(NASDAQ:KURA),(NASDAQ:BMEA),(NYSE:JNJ) EQNX::TICKER_END

SNDX : 13.08 (+1.79%)
ATNM : 1.2900 (+15.18%)
KURA : 9.01 (+0.45%)
BMEA : 4.23 (+3.68%)
JNJ : 144.47 (+0.62%)
Acute Myeloid Leukemia is on the Rise as Biotechs Race to Develop Groundbreaking Therapies GlobeNewswire - Mon Jun 17, 8:00AM CDT

SNDX : 13.08 (+1.79%)
ATNM : 1.2900 (+15.18%)
KURA : 9.01 (+0.45%)
BMEA : 4.23 (+3.68%)
JNJ : 144.47 (+0.62%)
Biopharma Stocks Quest for Solutions for Acute Myeloid Leukemia (AML) Newsfile - Mon Jun 17, 7:50AM CDT

Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - June 17, 2024) - Investorideas.com, a go-to investing platform, releases the first of a two-part series looking at developments for the...

ATNM : 1.2900 (+15.18%)
Actinium Presents First Ever Data Demonstrating Statistically Significant Anti-Tumor Control and Potent Leukemic Cell Killing with Actimab-A in Combination with Leading Menin Inhibitors in Preclinical Acute Myeloid Leukemia Models at the 2024 EHA Congress FinancialNewsMedia - Mon Jun 17, 7:25AM CDT

Actimab-A enhances dose-dependent acute myeloid leukemia cell death in KMT2A sensitive acute myeloid leukemia blasts in combination with leading menin inhibitors Combination with leading menin inhibitor...

ATNM : 1.2900 (+15.18%)
Actinium Pharma Highlights Three Abstracts Accepted for Poster Presentation at the SOHO 2023 Annual Meeting PR Newswire - Thu Aug 31, 2023

/PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today...

ATNM : 1.2900 (+15.18%)

Barchart Exclusives

Scalp a 47% Payout by the End of This Week with Micron (MU) Call Spreads Barchart - Sat Dec 21, 9:15AM CST
Yes, there are serious questions about MU stock following the underlying company’s disappointing earnings but a steady march is all options traders need. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot